LAVA TherapeuticsLVTX
LVTX
About: LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
Employees: 34
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
66% more capital invested
Capital invested by funds: $6.15M [Q4 2024] → $10.2M (+$4.06M) [Q1 2025]
5.98% more ownership
Funds ownership: 24.62% [Q4 2024] → 30.6% (+5.98%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
9% less funds holding
Funds holding: 22 [Q4 2024] → 20 (-2) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.50
15%
upside
Avg. target
$1.50
15%
upside
High target
$1.50
15%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Arthur He | 15%upside $1.50 | Neutral Reiterated | 31 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million.
Neutral
GlobeNewsWire
2 months ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024.
Negative
Benzinga
3 months ago
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
On Tuesday, LAVA Therapeutics N.V. LVTX initiated a process to review strategic options.
Neutral
GlobeNewsWire
5 months ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Neutral
GlobeNewsWire
6 months ago
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, reported financial results for the third quarter ended September 30, 2024 and announced a strategic pipeline reprioritization.
Neutral
GlobeNewsWire
9 months ago
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference.
Neutral
GlobeNewsWire
9 months ago
LAVA Reports Second Quarter 2024 Financial Results and Business Update
UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2024 and provided an update on recent corporate highlights.
Positive
24/7 Wall Street
10 months ago
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
Positive
Zacks Investment Research
10 months ago
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Charts implemented using Lightweight Charts™